Adiponectin vs Insulin Aspart
Head-to-head comparison of Adiponectin (Adiponectin (Acrp30, AdipoQ)) and Insulin Aspart (Insulin aspart (B28-Asp human insulin analog)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Adiponectin | Insulin Aspart |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Adiponectin (Acrp30, AdipoQ) | Insulin aspart (B28-Asp human insulin analog) |
| Molecular Weight | ~26.4 kDa (monomer) | 5825.8 Da |
| Half-Life | ~2-4 h | About 1-3 hours |
| Amino Acids | 244 | 51 |
| Typical Dose | No approved human dose; research use only | 0.05-0.2 U/kg per meal |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 86 | 11000 |
| Research Status | Pre-clinical | Approved |
Adiponectin Benefits
- ✓insulin sensitivity
- ✓fatty-acid oxidation
- ✓AMPK activation
Insulin Aspart Benefits
- ✓Fast post-meal glucose lowering
- ✓Predictable onset
- ✓Flexible mealtime administration
- ✓Compatible with pump therapy
Adiponectin Dosing
not established|not established
Insulin Aspart Dosing
Inject SC immediately before meals|Titrate using glucose monitoring and carbohydrate intake|Can be used in insulin pumps or basal-bolus regimens
Adiponectin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Insulin Aspart Side Effects
- ⚠Hypoglycemia
- ⚠Injection-site reactions
- ⚠Weight gain
Research Overview
Adiponectin
Preclinical and translational studies link adiponectin signaling with better glycemic control, lower inflammation, and improved lipid handling. Recombinant adiponectin and receptor-targeting approaches remain research tools rather than approved diabetes therapies.
Insulin Aspart
Research consistently shows faster onset and earlier peak action than regular human insulin. It is commonly studied for meal-time glycemic control and pump-based insulin delivery.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.